

## Full Portfolio Holdings\* as of February 28, 2026

The value of holdings represents the market value for non-derivative positions and unrealized appreciation/(depreciation) for derivative positions.

Security	Coupon	Maturity	Shares/Par	Value	% of Net Assets
<b>BASE CURRENCY</b>					
US DOLLAR			6,051,279	6,051,279	0.73%
<b>COMMON STOCKS</b>					
Eli Lilly & Co.			99,129	104,282,717	12.52%
Merck & Co., Inc.			434,365	53,783,074	6.46%
Johnson & Johnson			182,752	45,401,079	5.45%
UnitedHealth Group, Inc.			119,582	35,069,813	4.21%
AbbVie, Inc.			134,406	31,192,944	3.75%
Intuitive Surgical, Inc.			59,745	30,082,205	3.61%
Abbott Laboratories			223,195	25,968,738	3.12%
Edwards Lifesciences Corp.			300,184	25,956,910	3.12%
Danaher Corp.			116,573	24,554,937	2.95%
Vertex Pharmaceuticals, Inc.			43,668	21,695,572	2.61%
Cencora, Inc.			50,660	18,852,612	2.26%
Boston Scientific Corp.			209,668	16,112,986	1.94%
HCA Healthcare, Inc.			27,119	14,364,934	1.73%
Thermo Fisher Scientific, Inc.			27,039	14,090,293	1.69%
CVS Health Corp.			172,712	13,799,689	1.66%
Elevance Health, Inc.			42,513	13,604,160	1.63%
Medtronic PLC			137,934	13,470,634	1.62%
Cardinal Health, Inc.			54,718	12,543,007	1.51%
Regeneron Pharmaceuticals, Inc.			16,034	12,533,297	1.51%
UCB SA			41,357	12,422,957	1.49%
GSK PLC			366,960	10,903,587	1.31%
Agilent Technologies, Inc.			85,683	10,400,203	1.25%
Stryker Corp.			26,694	10,342,857	1.24%
Dexcom, Inc.			125,860	9,241,900	1.11%
United Therapeutics Corp.			17,574	8,855,539	1.06%
Biogen, Inc.			44,436	8,523,714	1.02%
AstraZeneca PLC			40,756	8,495,588	1.02%
STERIS PLC			29,627	7,476,373	0.90%
Argenx SE			9,657	7,406,146	0.89%
Ionis Pharmaceuticals, Inc.			82,046	6,658,033	0.80%
Galderma Group AG			33,699	6,359,338	0.76%
Elanco Animal Health, Inc.			234,258	6,184,411	0.74%
Ascendis Pharma AS			25,754	6,013,559	0.72%
Bristol-Myers Squibb Co.			94,796	5,912,427	0.71%
Incyte Corp.			56,132	5,684,488	0.68%
Encompass Health Corp.			51,367	5,541,472	0.67%
Kymera Therapeutics, Inc.			58,333	5,328,720	0.64%
Option Care Health, Inc.			153,121	4,970,308	0.60%
Revolution Medicines, Inc.			48,346	4,932,259	0.59%
Madrigal Pharmaceuticals, Inc.			11,246	4,858,272	0.58%

Full Portfolio Holdings\* as of February 28, 2026

Security	Coupon	Maturity	Shares/Par	Value	% of Net Assets
Alnylam Pharmaceuticals, Inc.			14,479	4,820,349	0.58%
Protagonist Therapeutics, Inc.			51,036	4,699,395	0.56%
Disc Medicine, Inc.			69,500	4,630,090	0.56%
Cytokinetics, Inc.			73,424	4,568,441	0.55%
Alignment Healthcare, Inc.			233,573	4,489,273	0.54%
Avantor, Inc.			492,326	4,455,550	0.54%
Arcus Biosciences, Inc.			216,338	4,406,805	0.53%
Pharvaris NV			155,094	4,403,119	0.53%
Vaxcyte, Inc.			71,286	4,401,198	0.53%
Bio-Techne Corp.			74,072	4,370,248	0.52%
Qiagen NV			87,533	4,359,143	0.52%
ICON PLC			39,527	4,274,450	0.51%
HeartFlow, Inc.			178,475	4,133,481	0.50%
Acadia Healthcare Co., Inc.			168,556	3,950,953	0.47%
Xenon Pharmaceuticals, Inc.			90,277	3,902,675	0.47%
Oculus Holding AG			129,741	3,815,683	0.46%
PTC Therapeutics, Inc.			54,649	3,726,515	0.45%
Natera, Inc.			17,791	3,701,240	0.44%
Viridian Therapeutics, Inc.			124,120	3,646,646	0.44%
Mirum Pharmaceuticals, Inc.			39,488	3,644,348	0.44%
Celldex Therapeutics, Inc.			118,382	3,562,114	0.43%
Dianthus Therapeutics, Inc.			64,398	3,554,126	0.43%
Apogee Therapeutics, Inc.			50,578	3,540,460	0.43%
Structure Therapeutics, Inc.			55,153	3,473,536	0.42%
Soleno Therapeutics, Inc.			85,170	3,327,592	0.40%
Apellis Pharmaceuticals, Inc.			151,877	3,183,342	0.38%
Inspire Medical Systems, Inc.			48,409	3,122,865	0.38%
Mineralys Therapeutics, Inc.			105,815	3,096,147	0.37%
Nuvalent, Inc.			29,773	3,035,357	0.36%
Immunocore Holdings PLC			88,743	2,866,399	0.34%
Jiangsu Hengrui Pharmaceuticals Co. Ltd.			330,781	2,810,496	0.34%
Immunome, Inc.			121,838	2,663,379	0.32%
Scholar Rock Holding Corp.			58,010	2,568,103	0.31%
Trevi Therapeutics, Inc.			213,009	2,539,067	0.30%
Aktis Oncology, Inc.			121,856	2,452,961	0.29%
Crinetics Pharmaceuticals, Inc.			59,607	2,449,848	0.29%
Newamsterdam Pharma Co. NV			68,032	2,412,415	0.29%
GenFleet Therapeutics Shanghai, Inc.			669,000	2,343,048	0.28%
Adaptive Biotechnologies Corp.			106,631	1,708,229	0.21%
VeraDermics, Inc.			24,700	1,132,495	0.14%
CG oncology, Inc.			13,705	805,854	0.10%
Corvus Pharmaceuticals, Inc.			29,300	535,018	0.06%
Eikon Therapeutics, Inc.			30,700	423,046	0.05%
<b>FOREIGN CURRENCY</b>					
BRAZILIAN REAL			1,906,284	371,849	0.04%
DANISH KRONE			1,239	196	0.00%

Full Portfolio Holdings\* as of February 28, 2026

Security	Coupon	Maturity	Shares/Par	Value	% of Net Assets
EURO CURRENCY			117	138	0.00%
HONG KONG DOLLAR			37	5	0.00%
JAPANESE YEN			1	0.01	0.00%
<b>RIGHTS</b>					
Abiomed, Inc.		12/31/2099	7,416	7,564	0.00%
<b>SHORT-TERM INVESTMENTS</b>					
Fixed Income Clearing Corp.		3/2/2026	1,523,542	1,523,542	0.18%
<b>DERIVATIVES - FOREIGN CURRENCY EXCHANGE CONTRACTS (SPOT)</b>					
POUND STERLING		3/3/2026	(614,509)	(885)	0.00%
<b>TOTAL INVESTMENTS</b>				<b>833,830,936</b>	<b>100.15%</b>
<b>OTHER ASSETS LESS LIABILITIES</b>				<b>(1,213,894)</b>	<b>-0.15%</b>
<b>TOTAL NET ASSETS</b>				<b>832,617,042</b>	<b>100.00%</b>

\* This unaudited information is being presented pursuant to the Fund's Policy on Disclosure of Portfolio Holdings. Please see the Fund's Statement of Additional Information on [www.hartfordfunds.com](http://www.hartfordfunds.com) for a discussion of the Fund's policy. Holdings are provided for informational purposes only and should not be construed as a recommendation or investment advice. Portfolio holdings are as of the date noted and are subject to change at any time. Holdings may not be representative of current or future investments.

Unlike the Fund's regulatory filings, the portfolio data and its presentation in this document is not required to conform to Generally Accepted Accounting Principles (GAAP) and Securities and Exchange Commission (SEC) presentation requirements. Therefore, it may differ from that provided in the complete portfolio of investments in the annual and semiannual Financial Statements and Other Information filed with the SEC on Form N-CSR, and the complete portfolio of investments filed in the first and third quarter on Form N-PORT. In addition, the number of portfolio holdings listed above, which is sourced from the Fund's custodian, may differ from the "number of holdings" and related data points in the Fund Stats section of the webpage which is sourced from the sub-adviser.

**Investing involves risk, including the possible loss of principal. Investors should carefully consider a fund's investment objectives, risks, charges and expenses. This and other important information is contained in the fund's prospectus and summary prospectus, which can be obtained by visiting [hartfordfunds.com](http://hartfordfunds.com). Please read it carefully before investing.**

Mutual funds are distributed by Hartford Funds Distributors, LLC, Member FINRA. Advisory services are provided by Hartford Funds Management Company, LLC, an SEC registered investment adviser.

4673945 07/25